ELISpot and FluoroSpot Assay Market by Product (Assay Kit (T Cell and B Cell assay), Analyzer, Ancillary Products), Application (Transplant, Vaccines, Clinical Trials, Cancer), End User (Hospital, Labs, Research Institute) - Global Forecast to 2023

ELISpot及びFluoroSpotアッセイの世界市場予測(~2023年)

◆タイトル:ELISpot and FluoroSpot Assay Market by Product (Assay Kit (T Cell and B Cell assay), Analyzer, Ancillary Products), Application (Transplant, Vaccines, Clinical Trials, Cancer), End User (Hospital, Labs, Research Institute) - Global Forecast to 2023
◆商品コード:MD-6791
◆調査・発行会社:MarketsandMarkets
◆発行日:2018年12月7日
◆ページ数:112
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥615,850見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥724,850見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥888,350見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、ELISpot及びFluoroSpotアッセイの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、製品別分析、用途別分析、需要先別分析、地域別分析、ELISpot及びFluoroSpotアッセイの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

・イントロダクション
・エグゼクティブサマリー
・ELISpot及びFluoroSpotアッセイの世界市場:市場インサイト
・ELISpot及びFluoroSpotアッセイの世界市場:市場概観/市場動向
・ELISpot及びFluoroSpotアッセイの世界市場:市場シェア分析
・ELISpot及びFluoroSpotアッセイの世界市場:製品別分析/市場規模
・ELISpot及びFluoroSpotアッセイの世界市場:用途別分析/市場規模
・ELISpot及びFluoroSpotアッセイの世界市場:需要先別分析/市場規模
・ELISpot及びFluoroSpotアッセイの世界市場:地域別分析/市場規模
・ELISpot及びFluoroSpotアッセイのアジア市場規模予測
・ELISpot及びFluoroSpotアッセイのヨーロッパ市場規模予測
・ELISpot及びFluoroSpotアッセイのアメリカ市場規模予測
・ELISpot及びFluoroSpotアッセイの世界市場動向
・ELISpot及びFluoroSpotアッセイの世界市場:競争状況
・ELISpot及びFluoroSpotアッセイの世界市場:関連企業分析
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

“ELISpot and FluoroSpot Assay market to register a CAGR of 16.2% from 2018 to 2023”
The ELISpot and FluoroSpot market is projected to reach USD 287 million by 2023 from USD 135 million in 2018, at a CAGR of 16.2% during the forecast period. The rising global incidence of chronic diseases, increasing vaccine development to address the challenge of antimicrobial resistance, and technological advancements in ELISpot and FluoroSpot assay kits and analyzers, are factors expected to drive market growth during the forecast period. The use of FluoroSpot assays for multiple-analyte detection in a single well is also expected to provide opportunities for the growth of the market.

“Assay Kits are expected to account for a significant share of the market in 2018”
By product, the ELISpot and FluoroSpot market is segmented into assay kits, analyzers, and ancillary products. The assay kits segment is further subsegmented by utility, type, and analyte. In 2018, the assay kits segment is expected to account for the largest market share. This segment is also expected to grow at the highest CAGR during the forecast period. The rising incidence of chronic diseases and technological advancements are driving the growth of this product segment.
“Diagnostic applications to hold the majority share in the ELISpot and FluoroSpot market in 2018”
On the basis of application, the ELISpot and FluoroSpot market is segmented into research and diagnostic applications. In 2018, the diagnostics segment is expected to account for the larger share of the ELISpot and FluoroSpot market. The large share of this segment can be attributed to the rising global prevalence of infectious diseases and the increasing use of ELISpot kits for disease diagnosis.

“North America to dominate the ELISpot and FluoroSpot market in 2018”
North America which includes the US and Canada, is expected to account for the largest share of the ELISpot and FluoroSpot market. The large share of this market segment can be attributed to the increasing incidence of chronic diseases. In addition to this, the increasing focus on vaccine development is driving the growth of this market.

Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 – 20% , Tier 2 – 45%, and Tier 3 – 35%
• By Designation: C-level – 30%, Director-level – 20%, and Others – 50%
• By Region: North America – 35%, Europe – 24%, Asia – 25%, and RoW – 16%

Research Coverage
This report studies the ELISpot and FluoroSpot market based on product, application, end user, and region. The report also analyzes factors (such as drivers, opportunities, and challenges) affecting market growth. It evaluates opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total ELISpot and FluoroSpot market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on ELISpot and FluoroSpot products offered by the top 10 players in the ELISpot and FluoroSpot market. The report analyzes the ELISpot and FluoroSpot market by product, end user, application, and region

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various ELISpot and FluoroSpot across key geographic regions

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the ELISpot and FluoroSpot market

• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the ELISpot and FluoroSpot market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.2.1 MARKETS COVERED 15
1.2.2 YEARS CONSIDERED FOR THE STUDY 15
1.3 CURRENCY 16
1.4 LIMITATIONS 16
1.5 STAKEHOLDERS 16
2 RESEARCH METHODOLOGY 17
2.1 SECONDARY DATA 18
2.1.1 KEY DATA FROM SECONDARY SOURCES 18
2.1.2 PRIMARY DATA 19
2.1.2.1 Key data from primary sources 20
2.2 MARKET SIZE ESTIMATION 21
2.2.1 BOTTOM-UP APPROACH 21
2.2.2 TOP-DOWN APPROACH 22
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 23
2.4 ASSUMPTIONS FOR THE STUDY 24
3 EXECUTIVE SUMMARY 25
4 PREMIUM INSIGHTS 28
4.1 ELISPOT AND FLUOROSPOT: MARKET OVERVIEW 28
4.2 NORTH AMERICA: ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT (2018) 29
4.3 GEOGRAPHICAL SNAPSHOT OF THE ELISPOT AND FLUOROSPOT MARKET 30
5 MARKET OVERVIEW 31
5.1 INTRODUCTION 31
5.2 MARKET DYNAMICS 31
5.2.1 DRIVERS 32
5.2.1.1 Rising global incidence of chronic diseases 32
5.2.1.2 Increasing vaccine development to address the challenge of antimicrobial resistance 32
5.2.1.3 Technological advancements in ELISpot and FluoroSpot assay kits and analyzers 32
5.2.2 OPPORTUNITIES 33
5.2.2.1 Use of FluoroSpot assays for multiple-analyte detection in a single well 33

5.2.3 CHALLENGES 33
5.2.3.1 Availability of alternative detection technologies 33
6 ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT 34
6.1 INTRODUCTION 35
6.2 ASSAY KITS 36
6.2.1 ASSAY KITS MARKET, BY TECHNIQUE 37
6.2.1.1 ELISpot assay kits 37
6.2.1.1.1 Majority of kits available in the market are ELISpot kits 37
6.2.1.2 FluoroSpot assay kits 38
6.2.1.2.1 Increasing demand for multiple analyte detection and technological advancement are driving segmental growth 38
6.2.2 ASSAY KITS MARKET, BY UTILITY 38
6.2.2.1 Diagnostic kits 39
6.2.2.1.1 Diagnostic kits are six to eight times costlier than research kits 39
6.2.2.2 Research kits 39
6.2.2.2.1 Market growth driven by continued investment in vaccine research, clinical trials, and cancer research 39
6.2.3 ASSAY KITS MARKET, BY ANALYTE 40
6.2.3.1 T-Cell-based kits 40
6.2.3.1.1 Low concentrations of infection-released analytes necessitates use of T-cell-based kits 40
6.2.3.2 B-cell-based kits 41
6.2.3.2.1 Detection of B-cell-based antibodies is useful to study cell response post-infection/vaccination 41
6.2.3.3 Other analyte kits 41
6.3 ANALYZERS 42
6.3.1 ADOPTION OF ASSAY KITS WILL DRIVE THE USE OF ANALYZERS 42
6.4 ANCILLARY PRODUCTS 42
6.4.1 MARKET PLAYERS SUCH AS THERMO FISHER SCIENTIFIC PROVIDE ANCILLARY PRODUCTS 42
7 ELISPOT AND FLUOROSPOT MARKET, BY APPLICATION 44
7.1 INTRODUCTION 45
7.2 DIAGNOSTIC APPLICATIONS 46
7.2.1 INFECTIOUS DISEASES 47
7.2.1.1 Infectious diseases segment to dominate the diagnostic applications market during the forecast period 47
7.2.2 TRANSPLANTS 48
7.2.2.1 Growing incidence of infections caused during transplant procedures are driving the demand for ELISpot and FluoroSpot assays 48

7.3 RESEARCH APPLICATIONS 49
7.3.1 VACCINE DEVELOPMENT 50
7.3.1.1 Vaccine development segment to register the highest growth rate in the forecast period 50
7.3.2 CLINICAL TRIALS 50
7.3.2.1 Growing number of clinical trials are driving the demand for ELISpot and FluoroSpot assays 50
7.3.3 CANCER RESEARCH 52
7.3.3.1 Rising global prevalence of cancer is driving the growth of the ELISpot and FluoroSpot market 52
8 ELISPOT AND FLUOROSPOT MARKET, BY END USER 53
8.1 INTRODUCTION 54
8.2 HOSPITALS & CLINICAL LABORATORIES 55
8.2.1 HOSPITALS & CLINICAL LABORATORIES TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2018 55
8.3 RESEARCH INSTITUTES 56
8.3.1 RESEARCH INSTITUTES ARE THE FASTEST-GROWING END USERS OF THE ELISPOT AND FLUOROSPOT MARKET 56
8.4 BIOPHARMACEUTICAL COMPANIES 57
8.4.1 BIOPHARMACEUTICAL COMPANIES USE ELISPOT AND FLUOROSPOT ASSAYS FOR VACCINE DEVELOPMENT, CLINICAL TRIALS, AND CANCER RESEARCH 57
9 ELISPOT AND FLUOROSPOT MARKET, BY REGION 58
9.1 INTRODUCTION 59
9.2 NORTH AMERICA 60
9.2.1 US 62
9.2.1.1 The US will continue to dominate the North American ELISpot and FluoroSpot market during the forecast period 62
9.2.2 CANADA 63
9.2.2.1 High burden of chronic diseases in the country to drive the adoption of ELISpot and FluoroSpot assays 63
9.3 EUROPE 65
9.3.1 GERMANY 67
9.3.1.1 Germany to be the fastest-growing country in the European ELISpot and FluoroSpot market 67
9.3.2 UK 69
9.3.2.1 Rising prevalence of NCDs in the UK to drive market growth 69
9.3.3 FRANCE 70
9.3.3.1 Chronic NCDs form a key cause of death in France 70
9.3.4 REST OF EUROPE 72

9.4 ASIA PACIFIC 74
9.4.1 CHINA 76
9.4.1.1 China’s large vaccine industry provides favorable outlook for ELISpot and FluoroSpot assays 76
9.4.2 INDIA 78
9.4.2.1 High incidence of chronic diseases and growing vaccine R&D activity will contribute to market growth 78
9.4.3 JAPAN 79
9.4.3.1 Chronic NCDs are responsible for a large chunk of deaths in Japan 79
9.4.4 REST OF ASIA PACIFIC 81
9.5 REST OF THE WORLD 82
10 COMPETITIVE LANDSCAPE 84
10.1 OVERVIEW 84
10.2 MARKET RANKING ANALYSIS, 2017 85
10.2.1 TOP PLAYERS IN RESEARCH-USE KITS MARKET 85
10.2.2 TOP PLAYERS IN ELISPOT AND FLUOROSPOT ANALYZERS MARKET 86
10.3 KEY STRATEGIES 87
10.3.1 PRODUCT LAUNCHES 87
10.3.2 EXPANSIONS 87
10.3.3 AGREEMENTS 87
10.3.4 ACQUISITIONS 88
10.3.5 PATENTS 88
10.3.6 PRODUCT APPROVAL 88
11 COMPANY PROFILES 89
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
11.1 OXFORD IMMUNOTEC 89
11.2 CELLULAR TECHNOLOGY LIMITED (CTL) 91
11.3 MABTECH AB 93
11.4 BECTON, DICKINSON AND COMPANY 94
11.5 ABCAM 96
11.6 BIO-TECHNE 98
11.7 AUTOIMMUN DIAGNOSTIKA GMBH 100
11.8 BIOTECH INVESTISSEMENT GROUP 102
11.9 LOPHIUS BIOSCIENCES GMBH 103
11.10 U-CYTECH BIOSCIENCES 104

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

12 APPENDIX 105
12.1 INSIGHTS OF INDUSTRY EXPERTS 105
12.2 DISCUSSION GUIDE 106
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 108
12.4 AVAILABLE CUSTOMIZATIONS 110
12.5 RELATED REPORTS 110
12.6 AUTHOR DETAILS 111

LIST OF TABLES

TABLE 1 ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 35
TABLE 2 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY REGION,
2016–2023 (USD MILLION) 36
TABLE 3 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY TECHNIQUE,
2016-2023 (USD MILLION) 37
TABLE 4 ELISPOT ASSAY KITS MARKET, BY REGION, 2016-2023 (USD MILLION) 37
TABLE 5 FLUOROSPOT ASSAY KITS MARKET, BY REGION, 2015-2023 (USD MILLION) 38
TABLE 6 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY UTILITY,
2016-2023 (USD MILLION) 38
TABLE 7 DIAGNOSTIC KITS MARKET, BY REGION, 2016-2023 (USD MILLION) 39
TABLE 8 RESEARCH KITS MARKET, BY REGION, 2016-2023 (USD MILLION) 39
TABLE 9 ASSAY KITS MARKET, BY ANALYTE, 2016-2023 (USD MILLION) 40
TABLE 10 T-CELL-BASED KITS MARKET, BY REGION, 2016-2023 (USD MILLION) 40
TABLE 11 B-CELL-BASED KITS MARKET, BY REGION, 2016-2023 (USD MILLION) 41
TABLE 12 OTHER ANALYTE KITS MARKET, BY REGION, 2016-2023 (USD MILLION) 41
TABLE 13 ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY REGION,
2016-2023 (USD MILLION) 42
TABLE 14 ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET,
BY REGION, 2016-2023 (USD MILLION) 43
TABLE 15 ELISPOT AND FLUOROSPOT MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 45
TABLE 16 ELISPOT AND FLUOROSPOT MARKET FOR DIAGNOSTIC APPLICATIONS,
BY TYPE, 2016–2023 (USD MILLION) 46
TABLE 17 ELISPOT AND FLUOROSPOT MARKET FOR DIAGNOSTIC APPLICATIONS,
BY REGION, 2016–2023 (USD MILLION) 46
TABLE 18 ELISPOT AND FLUOROSPOT MARKET FOR INFECTIOUS DISEASES,
BY REGION, 2016–2023 (USD MILLION) 48
TABLE 19 ELISPOT AND FLUOROSPOT MARKET FOR TRANSPLANTS, BY REGION,
2016–2023 (USD MILLION) 48
TABLE 20 ELISPOT AND FLUOROSPOT MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2016–2023 (USD MILLION) 49
TABLE 21 ELISPOT AND FLUOROSPOT MARKET FOR RESEARCH APPLICATIONS,
BY REGION, 2016–2023 (USD MILLION) 49
TABLE 22 ELISPOT AND FLUOROSPOT MARKET FOR VACCINE DEVELOPMENT,
BY REGION, 2016–2023 (USD MILLION) 50
TABLE 23 ELISPOT AND FLUOROSPOT MARKET FOR CLINICAL TRIALS, BY REGION,
2016–2023 (USD MILLION) 51
TABLE 24 ELISPOT AND FLUOROSPOT MARKET FOR CANCER RESEARCH, BY REGION,
2016–2023 (USD MILLION) 52
TABLE 25 ELISPOT AND FLUOROSPOT MARKET, BY END USER, 2016–2023 (USD MILLION) 54
TABLE 26 ELISPOT AND FLUOROSPOT MARKET FOR HOSPITALS & CLINICAL LABORATORIES, BY REGION, 2016–2023 (USD MILLION) 55
TABLE 27 ELISPOT AND FLUOROSPOT MARKET FOR RESEARCH INSTITUTES, BY REGION, 2016–2023 (USD MILLION) 56
TABLE 28 ELISPOT AND FLUOROSPOT MARKET FOR BIOPHARMACEUTICAL COMPANIES,
BY REGION, 2016–2023 (USD MILLION) 57
TABLE 29 ELISPOT AND FLUOROSPOT MARKET, BY REGION, 2016–2023 (USD MILLION) 59
TABLE 30 NORTH AMERICA: ELISPOT AND FLUOROSPOT MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 61
TABLE 31 NORTH AMERICA: ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 61
TABLE 32 NORTH AMERICA: ELISPOT AND FLUOROSPOT MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 61
TABLE 33 NORTH AMERICA: ELISPOT AND FLUOROSPOT MARKET, BY END USER,
2016–2023 (USD MILLION) 62
TABLE 34 US: ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 62
TABLE 35 US: ELISPOT AND FLUOROSPOT MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 63
TABLE 36 US: ELISPOT AND FLUOROSPOT MARKET, BY END USER,
2016–2023 (USD MILLION) 63
TABLE 37 CANADA: ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT,
2018–2023 (USD MILLION) 64
TABLE 38 CANADA: ELISPOT AND FLUOROSPOT MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 64
TABLE 39 CANADA: ELISPOT AND FLUOROSPOT MARKET, BY END USER,
2016–2023 (USD MILLION) 64
TABLE 40 EUROPE: ELISPOT AND FLUOROSPOT MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 65
TABLE 41 EUROPE: ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 66
TABLE 42 EUROPE: ELISPOT AND FLUOROSPOT MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 66
TABLE 43 EUROPE: ELISPOT AND FLUOROSPOT MARKET, BY END USER,
2016–2023 (USD MILLION) 66
TABLE 44 GERMANY: ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 67
TABLE 45 GERMANY: ELISPOT AND FLUOROSPOT MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 68
TABLE 46 GERMANY: ELISPOT AND FLUOROSPOT MARKET, BY END USER,
2016–2023 (USD MILLION) 68
TABLE 47 UK: ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 69
TABLE 48 UK: ELISPOT AND FLUOROSPOT MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 70
TABLE 49 UK: ELISPOT AND FLUOROSPOT MARKET, BY END USER,
2016–2023 (USD MILLION) 70
TABLE 50 FRANCE: ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 71
TABLE 51 FRANCE: ELISPOT AND FLUOROSPOT MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 72
TABLE 52 FRANCE: ELISPOT AND FLUOROSPOT MARKET, BY END USER,
2016–2023 (USD MILLION) 72
TABLE 53 ROE: ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 73
TABLE 54 ROE: ELISPOT AND FLUOROSPOT MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 73
TABLE 55 ROE: ELISPOT AND FLUOROSPOT MARKET, BY END USER,
2016–2023 (USD MILLION) 73
TABLE 56 ASIA PACIFIC: ELISPOT AND FLUOROSPOT MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 75
TABLE 57 ASIA PACIFIC: ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 75
TABLE 58 ASIA PACIFIC: ELISPOT AND FLUOROSPOT MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 76
TABLE 59 ASIA PACIFIC: ELISPOT AND FLUOROSPOT MARKET, BY END USER,
2016–2023 (USD MILLION) 76
TABLE 60 CHINA: ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 77
TABLE 61 CHINA: ELISPOT AND FLUOROSPOT MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 77
TABLE 62 CHINA: ELISPOT AND FLUOROSPOT MARKET, BY END USER,
2016–2023 (USD MILLION) 77
TABLE 63 INDIA: ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 78
TABLE 64 INDIA: ELISPOT AND FLUOROSPOT MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 79
TABLE 65 INDIA: ELISPOT AND FLUOROSPOT MARKET, BY END USER,
2016–2023 (USD MILLION) 79
TABLE 66 JAPAN: ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 80
TABLE 67 JAPAN: ELISPOT AND FLUOROSPOT MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 80
TABLE 68 JAPAN: ELISPOT AND FLUOROSPOT MARKET, BY END USER,
2016–2023 (USD MILLION) 80
TABLE 69 ROAPAC: ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 81
TABLE 70 ROAPAC: ELISPOT AND FLUOROSPOT MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 81
TABLE 71 ROAPAC: ELISPOT AND FLUOROSPOT MARKET, BY END USER,
2016–2023 (USD MILLION) 82
TABLE 72 ROW: ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 82
TABLE 73 ROW: ELISPOT AND FLUOROSPOT MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 83
TABLE 74 ROW: ELISPOT AND FLUOROSPOT MARKET, BY END USER,
2016–2023 (USD MILLION) 83



LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 17
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 19
FIGURE 3 ELISPOT AND FLUOROSPOT MARKET: BOTTOM-UP APPROACH 21
FIGURE 4 ELISPOT AND FLUOROSPOT MARKET: TOP-DOWN APPROACH 22
FIGURE 5 DATA TRIANGULATION METHODOLOGY 23
FIGURE 6 ELISPOT AND FLUOROSPOT MARKET, BY PRODUCT, 2018 VS. 2023 (USD MILLION) 25
FIGURE 7 ELISPOT AND FLUOROSPOT MARKET, BY APPLICATION,
2018 VS. 2023 (USD MILLION) 26
FIGURE 8 ELISPOT AND FLUOROSPOT MARKET, BY END USER,
2018 VS. 2023 (USD MILLION) 26
FIGURE 9 ELISPOT AND FLUOROSPOT MARKET, BY REGION, 2018 VS. 2023 (USD MILLION) 27
FIGURE 10 RISING GLOBAL INCIDENCE OF CHRONIC DISEASES AND FOCUS ON VACCINE DEVELOPMENT TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD 28
FIGURE 11 ASSAYS KITS TO DOMINATE THE NORTH AMERICAN ELISPOT AND FLUOROSPOT MARKET IN 2018 29
FIGURE 12 COUNTRIES IN ASIA TO REGISTER A HIGHER GROWTH RATE DURING
THE FORECAST PERIOD 30
FIGURE 13 ELISPOT AND FLUOROSPOT MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 31
FIGURE 14 ASSAY KITS SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 35
FIGURE 15 DIAGNOSTIC APPLICATIONS TO DOMINATE THE ELISPOT AND FLUOROSPOT MARKET DURING THE FORECAST PERIOD 45
FIGURE 16 TOTAL CASES OF TICK-BORNE DISEASES IN THE US, 2004–2017 47
FIGURE 17 PERCENTAGE OF REGISTERED STUDIES BY LOCATION
(AS OF NOVEMBER 26, 2018) 51
FIGURE 18 RESEARCH INSTITUTES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 54
FIGURE 19 ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH IN THE ELISPOT AND FLUOROSPOT MARKET DURING THE FORECAST PERIOD 59
FIGURE 20 NORTH AMERICA: ELISPOT AND FLUOROSPOT MARKET SNAPSHOT 60
FIGURE 21 GLOBAL VACCINE PRODUCTION 65
FIGURE 22 NON-COMMUNICABLE DISEASES IN GERMANY 67
FIGURE 23 NON-COMMUNICABLE DISEASES IN THE UK 69
FIGURE 24 NON-COMMUNICABLE DISEASES IN FRANCE 71
FIGURE 25 ASIA PACIFIC: ELISPOT AND FLUOROSPOT MARKET SNAPSHOT 74
FIGURE 26 KEY DEVELOPMENTS IN THE ELISPOT AND FLUOROSPOT MARKET
FROM 2015 TO 2018 84
FIGURE 27 ELISPOT AND FLUOROSPOT MARKET RANKING, BY KEY PLAYER, 2017 85
FIGURE 28 TOP PLAYERS IN RESEARCH-USE KITS MARKET 86
FIGURE 29 TOP PLAYERS IN ELISPOT AND FLUOROSPOT ANALYZERS MARKET 86

FIGURE 30 OXFORD IMMUNOTEC: COMPANY SNAPSHOT (2017) 89
FIGURE 31 BD: COMPANY SNAPSHOT (2017) 94
FIGURE 32 ABCAM: COMPANY SNAPSHOT (2017) 96
FIGURE 33 BIO-TECHNE: COMPANY SNAPSHOT (2017) 98




【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[ELISpot及びFluoroSpotアッセイの世界市場予測(~2023年)]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆